A study of healthcare workers demonstrated that the presence of antibody to SARS-CoV-2 spike protein or to nucleocapsid provides strong protection against infection with this virus for up to six months.
Administration of convalescent plasma obtained from survivors of COVID-19 within 72 hours of onset of mild symptoms in elderly patients with COVID-19 was associated with a significant reduction in the risk of development of severe respiratory disease.
Repeat infection with endemic seasonal coronavirus occurs commonly and raises concerns about immunity to SARS-CoV-2 as well as about the efficacy of vaccines in the protection against infection because of this virus.
While antibody tests are broadly seen as a way to determine immunity and exposure to the pandemic coronavirus, the Food and Drug Administration recently warned that tests should not be used as the “sole basis to diagnose COVID-19.”
Based on an observational prospective study of 16 patients with anti-myelin oligodendrocyte protein (MOG) disease and 29 anti-aquaporin-4 disease, the authors report lesser efficacy of rituximab in anti-MOG patients, characterized by higher occurrence of relapses in the anti-MOG group, even while the biological effect of rituximab on memory B-cell suppression was sustained.
This retrospective study of 121 patients with stiff-person spectrum disorder extensively examined antibody correlates of clinical features. Anti-GAD65 antibodies were highly associated with typical stiff-person syndrome, and anti-GlyR antibodies with SPS-plus. However, presence of anti-GAD antibodies predicted worse outcome than presence of antiGlyR antibodies, independent of clinical subtype.